Troglitazone

Caroline Day; Clifford J. Bailey

doi:10.1016/B978-008055232-3.62812-0

Troglitazone

Caroline Day^*, Clifford J. Bailey

^*Corresponding author for this work

Research output: Chapter in Book/Published conference output › Chapter (peer-reviewed) › peer-review

Abstract

Troglitazone was the first thiazolidinedione antihyperglycemic agent to be introduced for the treatment of type 2 diabetes mellitus. It was introduced in 1997, but withdrawn almost immediately (UK) or by 2000 (USA) as evidence emerged of fatal idiosyncratic hepatotoxicity... © 2007

Original language	English
Title of host publication	xPharm
Subtitle of host publication	the comprehensive pharmacology reference
Publisher	Elsevier
Number of pages	3
ISBN (Print)	978-0-08-055232-3
DOIs	https://doi.org/10.1016/B978-008055232-3.62812-0
Publication status	Published - Feb 2011

Access to Document

10.1016/B978-008055232-3.62812-0

Cite this

@inbook{af878b1f8d4b4a5bb37709aa4b96eb76,

title = "Troglitazone",

abstract = "Troglitazone was the first thiazolidinedione antihyperglycemic agent to be introduced for the treatment of type 2 diabetes mellitus. It was introduced in 1997, but withdrawn almost immediately (UK) or by 2000 (USA) as evidence emerged of fatal idiosyncratic hepatotoxicity... {\textcopyright} 2007",

author = "Caroline Day and Bailey, {Clifford J.}",

year = "2011",

month = feb,

doi = "10.1016/B978-008055232-3.62812-0",

language = "English",

isbn = "978-0-08-055232-3",

booktitle = "xPharm",

publisher = "Elsevier",

address = "Netherlands",

}

TY - CHAP

T1 - Troglitazone

AU - Day, Caroline

AU - Bailey, Clifford J.

PY - 2011/2

Y1 - 2011/2

N2 - Troglitazone was the first thiazolidinedione antihyperglycemic agent to be introduced for the treatment of type 2 diabetes mellitus. It was introduced in 1997, but withdrawn almost immediately (UK) or by 2000 (USA) as evidence emerged of fatal idiosyncratic hepatotoxicity... © 2007

AB - Troglitazone was the first thiazolidinedione antihyperglycemic agent to be introduced for the treatment of type 2 diabetes mellitus. It was introduced in 1997, but withdrawn almost immediately (UK) or by 2000 (USA) as evidence emerged of fatal idiosyncratic hepatotoxicity... © 2007

UR - http://www.scopus.com/inward/record.url?scp=84884078690&partnerID=8YFLogxK

U2 - 10.1016/B978-008055232-3.62812-0

DO - 10.1016/B978-008055232-3.62812-0

M3 - Chapter (peer-reviewed)

SN - 978-0-08-055232-3

BT - xPharm

PB - Elsevier

ER -

Troglitazone

Abstract

Access to Document

Other files and links

Fingerprint

Biguanides

Ciglitazone

Metformin

Cite this